Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Offer Update

29 Jul 2005 18:04

Torex Retail PLC29 July 2005 Torex Retail plc29 July 2005 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN TOREX RETAIL PLC ___________________________________________________________________________ RECOMMENDED OFFER FOR XN CHECKOUT HOLDINGS PLC Offer Unconditional as to Acceptances As at 1.00 p.m. on 29 July 2005, valid acceptances had been received in respectof 24,777,251 XN Checkout Shares (representing approximately 89.19 per cent ofXN Checkout's issued share capital). Accordingly, the Board of Torex Retail plc("Torex Retail") announces that the offer (the "Offer") made by EvolutionSecurities Limited on behalf of Torex Retail for XN Checkout Holdings PLC ("XNCheckout") has been declared unconditional as to acceptances. The Offer remains conditional upon the admission to trading on AiM of the newTorex Shares issued as consideration under the Offer ("New Torex Shares")becoming effective. Application has therefore been made for the admission of 63,107,579 New TorexShares to trading on AiM and it is expected that these New Torex Shares will beadmitted to trading on AiM and that dealings in those shares will commence on 4August 2005, when it is also expected that the Offer will become whollyunconditional. Save for the holding of Christopher Moore (Chief Executive of Torex Retail andNon-Executive Chairman of XN Checkout) of 2,580,497 XN Checkout Shares, neitherTorex Retail nor any persons deemed to be acting in concert with it for thepurposes of the Offer owned any XN Checkout Shares (or rights over such shares)on 3 June 2005 (being the last dealing day prior to the commencement of theOffer period) nor has Torex Retail nor any person deemed to be acting in concertwith it for the purposes of the Offer acquired or agreed to acquire any XNCheckout Shares (or rights over such shares) during the Offer period other thanby way of acceptances of the Offer. On 10 June 2005, Torex Retail announced that irrevocable undertakings to acceptthe Offer had been received from XN Checkout Shareholders who, in aggregate,have an interest in 10,540,085 XN Checkout Shares. Valid acceptances have beenreceived in respect of 8,500,718 of these XN Checkout Shares (representingapproximately 30.60 per cent of XN Checkout's issued share capital) and theseare included in the total above. In respect of the balance of 2,039,367 XNCheckout Shares, the acceptance form has been received duly signed, but without,as yet, sufficient supporting documentation to treat it as a valid acceptanceand therefore has not been included in the total above. The Offer will remain open until further notice. At least 14 days' notice willbe given before the Offer is closed. Terms defined in the formal Offer document dated 8 July 2005 shall, unless thecontext requires otherwise, have the same meanings in this announcement. EnquiriesTorex Retail Telephone: 01993 230 030Richard Thompson / Nigel Horn Evolution Telephone: 0207 071 4300Tim Worlledge / Jeremy Ellis This announcement is issued by Evolution which is authorised and regulated inthe United Kingdom by the Financial Services Authority. Evolution is actingexclusively for Torex Retail and is acting for no one else in connection withthe Offer and will not be responsible to anyone other than Torex Retail forproviding the protections afforded to customers of Evolution nor for providingadvice in relation to the Offer. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
12th Oct 20167:00 amRNSInterim Results
28th Sep 20167:00 amRNSNotice of Interim Results
15th Sep 20163:07 pmRNSEdison issues outlook on Tissue Regenix
1st Sep 20167:00 amRNSDermaPure® Medicare coverage in further 10 States
3rd Aug 20167:15 amRNSHardman & Co Research Report on: Tissue Regenix
28th Jul 201610:58 amRNSEdison research outlook on Tissue Regenix (TRX)
18th Jul 201611:20 amRNSTR1- NOTIFICATION OF MAJOR INTEREST IN SHARES
11th Jul 20167:00 amRNSOrthopaedics Update
4th Jul 201610:41 amRNSResult of AGM
1st Jul 20167:00 amRNSDermaPure® secures first GPO contract in US
30th Jun 20167:00 amRNSDeferred Annual Bonus Scheme
1st Jun 20167:00 amRNSNew appointment adds clinical expertise to Board
23rd May 20167:00 amRNSPreliminary results for year ended 31 January 2016
20th Apr 20167:00 amRNSNotice of Preliminary Results
14th Apr 20167:00 amRNSChange of Registered Office
24th Mar 20164:40 pmRNSSecond Price Monitoring Extn
24th Mar 20164:35 pmRNSPrice Monitoring Extension
11th Mar 20163:02 pmRNSTR1- NOTIFICATION OF MAJOR INTEREST IN SHARES
9th Mar 20167:00 amRNS510k market clearance granted for SurgiPureT XD
9th Mar 20167:00 amRNSFurther Medicare Coverage for DermaPure®
11th Feb 20167:00 amRNSVP, Orthopaedic, Inc. North America appointed
3rd Feb 20167:00 amRNSDermaPure to be Showcased in Nine Posters at SAWC
26th Jan 201612:21 pmRNSJoint Venture Agreement
25th Jan 20167:00 amRNSHardman & Co Research Report
20th Jan 20167:00 amRNSDermaPure® breaks through $1m sales mark
19th Jan 20167:00 amRNSAppointment of Non-Executive Director
18th Jan 20167:00 amRNSOrthoPureT XM clinical trial enrolment completed
23rd Dec 201512:40 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
4th Dec 20157:00 amRNSOrthoPureT XT implants successfully undertaken
5th Nov 20154:42 pmRNSIssue of equity and total voting rights
26th Oct 20157:00 amRNSIssue of equity and total voting rights
23rd Oct 20157:49 amRNSNon-Executive Director Share Purchase
14th Oct 20154:09 pmRNSEdison initiates coverage of Tissue Regenix
12th Oct 20157:00 amRNSInterim Results
4th Sep 201510:11 amRNSNotice of Interim Results and Capital Markets Day
30th Jul 20157:00 amRNSFurther Medicare Coverage Approval for DermaPure
22nd Jul 20157:00 amRNSAdditional US regional distribution agreement
26th Jun 20157:00 amRNSFurther Medicare Coverage Approval for DermaPure®
12th Jun 201512:43 pmRNSResult of AGM
1st Jun 20159:17 amRNSDermaPure saves 18 year old's leg from frost bite
21st May 20159:51 amRNSHolding(s) in Company
20th May 20157:00 amRNSEmployee SAYE Share Plan
12th May 20157:00 amRNSDeferred Annual Bonus Award
11th May 20157:00 amRNSFinal Results
11th May 20157:00 amRNSFurther Medicare Coverage Approval for DermaPure
5th May 20157:02 amRNSUS regional distribution agreement signed
1st May 20154:01 pmRNSHolding(s) in Company
29th Apr 20157:01 amRNSDermaPure US Clinical data to be presented at SAWC
28th Apr 20157:00 amRNSOrthoPureT XT (Tendon) UK Clinical Trial Approval
9th Mar 20152:05 pmRNSNotice of Preliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.